Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-11-16 Report Publication Anno…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PureTech to Present at Three Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is identified by the RNS Number header and the distribution source (RNS, London Stock Exchange). The content announces that members of the Management Team will present at three upcoming virtual investor conferences, detailing the conference names, dates, and presenters. This is an announcement about future investor engagement, which aligns best with an Investor Presentation (IP) if it were the presentation itself, or more generally, a regulatory announcement. Since it is an announcement about future investor events rather than a specific financial report, a director's dealing, or a formal meeting result, and it is distributed via RNS, it fits the description of a general regulatory announcement. Given the options, 'Investor Presentation' (IP) is plausible if the content were the presentation slides, but since it is an announcement *about* presentations, and it is distributed via RNS, it is best classified as a general regulatory filing or announcement. However, since the core subject is informing investors about upcoming presentations, 'Investor Presentation' (IP) is often used for materials related to investor outreach, but 'Regulatory Filings' (RNS) is the designated fallback for general regulatory announcements. Given the context of informing investors about conference participation, 'IP' is a strong candidate, but 'RNS' covers general announcements distributed through that system. Let's re-evaluate the definitions. It is not a DEF 14A (Remuneration), DIRS (Director's Dealing), or DIV (Dividend). It is not an ER (Earnings Release) or IR (Interim Report). It is an announcement about future investor events. This type of announcement is often categorized under 'RNS' as a general regulatory update, or sometimes 'IP' if the focus is purely on investor relations material dissemination. Since it is a press release distributed via RNS announcing participation in investor conferences, 'RNS' (Regulatory Filings) is the most appropriate general category for this type of market communication that doesn't fit a more specific financial report type.
2020-11-16 English
Guidance for Exchanging Ordinary Shares into ADSs
Regulatory Filings Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC dated November 13, 2020. The primary subject is providing instructions for existing London Stock Exchange (LSE) listed Ordinary Shareholders on how to exchange those shares into American Depository Shares (ADSs) listed on the Nasdaq Global Market. This involves detailing the process, fees, and required documentation (like the 'PureTech Health plc - UK ADS Creation - SDRT Certification') for the exchange, which is a corporate action related to capital structure/listing mechanics. Since the document is an announcement detailing a process for a corporate action (dual listing/share conversion) and is distributed via RNS, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not the final financial report (10-K, IR), a management discussion (MDA), or a specific capital change announcement (CAP/SHA), but rather a procedural notice distributed through the regulatory news service.
2020-11-13 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Notification of Transactions of Directors/Persons Discharging Managerial Responsibility' (PDMR DEALING NOTIFICATION) concerning the conversion of Ordinary Shares to ADS's by the CEO's related trusts. This type of insider transaction reporting, mandated under Article 19 of the Market Abuse Regulation, is a specific regulatory disclosure. While it is a regulatory filing, the specific nature of reporting director/insider transactions points strongly towards the 'Director's Dealing' category (DIRS). It is not a general regulatory announcement (RNS) but a specific type of insider trade report.
2020-11-13 English
Regulatory Filings 2020
Regulatory Filings
2020-11-13 English
Gelesis Presents New Data at The Liver Meeting
Regulatory Filings Classification · 99% confidence The document is an announcement released via RNS (RNS Number: 2000F) by PureTech Health plc on November 13, 2020. The content details positive pre-clinical data regarding its Founded Entity, Gelesis, and its hydrogel product (GS300) presented at a medical conference (AASLD's The Liver Meeting). This is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement. It is a specific announcement about scientific/clinical progress, which often falls under general regulatory announcements or investor relations updates. Since it is a specific update about a clinical/scientific finding, and not a general regulatory filing fallback (RNS), it is best classified as an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the context of reporting scientific findings to investors, and the fact that it is an announcement about data presented at a meeting, it aligns closely with the spirit of an Investor Presentation (IP) or a general regulatory announcement. However, since the core content is the announcement of scientific data presentation, and it is distributed via RNS, the most appropriate specific category that covers non-financial, non-management, non-legal updates that are intended for investors is often the general Regulatory Filing (RNS) if a more specific category like 'IP' (Investor Presentation) isn't explicitly about a slide deck. Since this is a press release announcing data, and it is distributed through the RNS system, RNS is the safest general classification for non-standard reports. If the document were the actual poster/presentation slides, IP would be better. As it is a press release announcing the presentation, RNS is appropriate as a regulatory announcement.
2020-11-13 English
PureTech to Commence Nasdaq Trading on 16 November
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 2013F' and concludes with boilerplate text referencing 'RNS, the news service of the London Stock Exchange.' This indicates it is a regulatory announcement disseminated via the RNS system. The content announces the commencement of trading on Nasdaq and the filing of Form 20-F and Form F-6 with the SEC. Since this is a general, time-sensitive regulatory announcement that doesn't fit the specific categories like ER, DIV, or CAP, and it is short and serves as a notification of an event (the listing), the most appropriate classification is Regulatory Filings (RNS), which acts as a general regulatory announcement category.
2020-11-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.